BioSpace News Archive

ColonaryConcepts LLC announced the reacquisition of its proprietary colonoscopy preparation assets from Sebela Pharmaceuticals.

Zentalis Pharmaceuticals (the “Company” or “Zentalis”), today announced that the U.S. Food and Drug Administration (FDA) has previously cleared its Investigational New Drug (IND) application for its third oncology drug candidate, ZN-c3, and that it has dosed the first patient in a Phase 1/2 clinical trial evaluating ZN-c3 in patients with advanced solid tumors

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced that it has entered into a $8.0 million secured term loan with Silicon Valley Bank (SVB),

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tucatinib, in combination with trastuzumab and capecitabine, for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have been treated with trastuzumab, pertuzumab, and T-DM1.

A research team at Konkuk University in Seoul, South Korea developed a new alcoholic fermentation method using an electrospray cell patterning technology.

XCR Diagnostics announced today that it has appointed Chuck Morrison, a seasoned medical diagnostics expert, to its Board of Directors.

Surescripts Network Alliance™ Prepares to Implement NCPDP SCRIPT Version 2017071 E-Prescribing Standard for Improved Prescription Accuracy, Patient Safety and Workflow Efficiency

TheraLight’s award-winning and innovative full-body photobiomodulation system nominated, and finalists to be announced in February

Pfizer Inc. (NYSE: PFE) and Mylan N.V. (NASDAQ: MYL) today announced that Ian Read and James Kilts will join the Viatris board of directors upon completion of the planned combination of Mylan N.V. and Upjohn Inc., which is expected to occur in mid-2020.

Zoetis Inc. (NYSE:ZTS) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2020, in San Francisco, Calif. Kristin Peck, who will become Chief Executive Officer of Zoetis on January 1, 2020, will represent the company and respond to questions from analysts.